Keywords: Brazil, Lung cancer, Market, Forecasts, Roche, Lilly, AstraZeneca
Brazil's NSCLC cancer drug market will reach $240 million by 2014, new study shows
Article | 08 July 2010
The non-small-cell lung cancer (NSCLC) drug market in Brazil will reach a value $240 million by 2014, according to a new report ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
